TOP TEN perturbations for 1553022_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553022_at
Selected probe(set): 1553022_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553022_at (1553022_at) across 6673 perturbations tested by GENEVESTIGATOR:

necrotizing myopathy study 2 / inclusion body myositis study 2

Relative Expression (log2-ratio):0.84667015
Number of Samples:2 / 5
Experimental necrotizing myopathy study 2
Quadriceps femoris biopsy muscle samples from patients with clinical diagnosis of necrotizing myopathy (NM).
Control inclusion body myositis study 2
Quadriceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).

hepatitis C study 6 (under treatment; non-responder) / hepatitis C study 6 (before treatment)

Relative Expression (log2-ratio):-0.59592247
Number of Samples:5 / 9
Experimental hepatitis C study 6 (under treatment; non-responder)
Microdissected liver-infiltrating lymphocyte (lilym) samples obtained after liver tissue biopsy from chronic hepatitis C (CH-C) patients after treatment with interferon-alpha 2b (IFN-a 2b) and ribavirin (Rib) in combination. Patients received IFN-a 2b (6 MU , every day for 2 weeks, then three times a week for 22 weeks) and Ribavirin (10–13 mg/kg/day) combination therapy for 24 weeks. Individuals had no treatment success and were for that non-responders after HCV viremia detected at the cessation of therapy.
Control hepatitis C study 6 (before treatment)
Microdissected liver-infiltrating lymphocyte (lilym) samples obtained after liver tissue biopsy from chronic hepatitis C (CH-C) patients before treatment with interferon-alpha 2b (IFN-a 2b) and ribavirin (Rib).

TBTO study 1 (24h) / vehicle (EtOH) treated HepG2 cell sample

Relative Expression (log2-ratio):0.5173373
Number of Samples:2 / 6
Experimental TBTO study 1 (24h)
HepG2 cells exposed to 0.02nM tributylinoxide (TBTO) in EtOH solvent for 24 hours. ATC code:---
Control vehicle (EtOH) treated HepG2 cell sample
HepG2 cells exposed to EtOH solvent for 24 hours.

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):0.51461697
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

T-cell isolation study 5 / T-cell isolation study 1

Relative Expression (log2-ratio):0.49693584
Number of Samples:2 / 2
Experimental T-cell isolation study 5
CD4+ resting memory T-cell were isolated from whole peripheral blood of healthy donors with no delay. The cell fraction was first enriched by erythrocyte lysis combined with MACS depletion of CD15+ cells (neutrophil granulocytes) and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population.
Control T-cell isolation study 1
CD4+ resting memory T-cell were isolated from whole peripheral blood of healthy donors with no delay. The cell fraction was first enriched with MACS for CD4+ cells and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population.

ovarian tumor study 16 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):0.45386934
Number of Samples:3 / 5
Experimental ovarian tumor study 16
Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue.

glioma study 17 (oligodendroglioma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-0.44573212
Number of Samples:3 / 4
Experimental glioma study 17 (oligodendroglioma; unsorted)
Brain cells isolated from low grade oligodendroglioma (grade II). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 39 ± 9 years old.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

Parkinson's disease study 3 / normal subthalamic nucleus tissue

Relative Expression (log2-ratio):0.43176556
Number of Samples:2 / 9
Experimental Parkinson's disease study 3
Subthalamic nucleus tissue from patients with Parkinson's disease.
Control normal subthalamic nucleus tissue
Normal subthalamic nucleus tissue.

acrolein study 1 (2800ug/ml) / vehicle (EtOH) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):-0.42349625
Number of Samples:2 / 3
Experimental acrolein study 1 (2800ug/ml)
Bronchial epithelial cells (NHBE) treated with 2800 ug/ml acrolein (within range of concentrations reported to induce toxicity in lung epithelial cells and other cell types) for 4 hours. NHBE cells were derived from a 60 year old male non-smoker. ATC code:---
Control vehicle (EtOH) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (ethanol) at a final concentration of 2% v/v (concentration that ensures >80% cell viability after 24 hours of exposure) for 4 hours. NHBE cells were derived from a 60 year old male non-smoker.

actinic keratosis study 4 (lesion; baseline) / uninvolved skin sample (baseline)

Relative Expression (log2-ratio):-0.41390848
Number of Samples:6 / 5
Experimental actinic keratosis study 4 (lesion; baseline)
Punch biopsies of skin lesions obtained from actinic keratosis (AK) patients before treatment (baseline). The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm.
Control uninvolved skin sample (baseline)
Punch biopsies of uninvolved skin obtained from actinic keratosis (AK) patients before treatment (baseline). Samples were taken from cca 25 cm2 area of uninvolved, normal-appearing, aged but non-sun-exposed skin on the inner aspect of the upper arm. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm.